Category : Crohn

Prediction of complications in Crohn’s disease Risk factors:-Age below 40 y-Disease location-perianal at diagnosis-requirement of steroid treatment in first flare References: Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130(3):650-656. doi:10.1053/j.gastro.2..

Read more

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane 2015 Related articles (Crohn):*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) ..

Read more

Methotrexate compared to placebo for induction of remission in refractory Crohn’s disease. Related articles (Crohn):*Azathioprine Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) For ..

Read more

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial Cyriel Y Ponsioen, E Joline de Groof , Emma J Eshuis , Tjibbe J Gardenbroek , Patrick M M Bossuyt, Ailsa Hart, Janindra Warusavitarne, Christianne J Buskens, Ad A van Bodegraven, Menno A Brink, Esther C J Consten, Bart A van Wagensveld, Marno C M Rijk, Rogier M P H Crolla, Casper G Noomen, Alexander P ..

Read more

Infliximab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Hanauer SB, ..

Read more

Infliximab with Azathiopurine (Crohn) Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease Jean Frédéric ..

Read more

Infliximab with Methotrexate (Crohn) Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in ..

Read more

Efficacy of anti-TNF maintenance therapy in Fistulas in Crohn’s Disease patients. In a meta-analysis it was found that TNF antagonists are effective for induction and maintenance of perianal fistula response and remission.  Efficacy of anti-TNF as induction therapy in fistulas Efficacy of anti-TNF as maintenance therapy in fistulas References: Lee, M. J., Parker, C. E., ..

Read more

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri, Neil Chanchlani, Neel M Heerasing, Peter Hendy, SimengLin, Daniel R Gaya, J R Fraser Cummings, Christian P ..

Read more

Infliximab switch to Adalimumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Background and Aims: In the 4-week GAIN clinical trial, adalimumab was efficacious ..

Read more

Ustekinumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Vedolizumab (GEMINI II – Crohn – 2013) BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was ..

Read more

Bruce E. Sands, William J. Sandborn, Gert Van Assche, Milan Lukas, Jing Xu, Alexandra James, Brihad Abhyankar, Karen Lasch, Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy, Inflammatory Bowel Diseases, Volume 23, Issue 1, 1 January 2017, Pages 97–106, https://doi.org/10.1097/MIB.0000000000000979 Background ..

Read more

Adalimumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Classic-I trial induction 2006 Background & aims: Tumor necrosis factor blockade has been shown ..

Read more

Adalimumab with immunomodulator in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Combination therapy anti-TNF (in this case Adalimumab/Humira) with immunomodulator, ..

Read more

Vedolizumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016) BackgroundThe efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn’s disease is unknown. MethodsIn ..

Read more

Ustekinumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Vedolizumab (GEMINI II – Crohn – 2013) BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was ..

Read more